blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3245602

EP3245602 - METHOD FOR INDIVIDUALIZED DRUG THERAPY [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  13.11.2020
Database last updated on 31.08.2024
FormerExamination is in progress
Status updated on  08.02.2020
FormerRequest for examination was made
Status updated on  20.10.2017
FormerThe international publication has been made
Status updated on  04.08.2017
Most recent event   Tooltip13.11.2020Application deemed to be withdrawnpublished on 16.12.2020  [2020/51]
Applicant(s)For all designated states
Autotelic LLC
17870 Castleton Street, Suite 250
City of Industry, CA 91748 / US
[2017/47]
Inventor(s)01 / TRIEU, Vuong
4003 Jim Bowie
Agoura Hills, California 91301 / US
 [2017/47]
Representative(s)Grund, Martin
Grund Intellectual Property Group
Patentanwälte und Solicitor PartG mbB
Steinsdorfstraße 2
80538 München / DE
[N/P]
Former [2017/47]Icosa
83 avenue Denfert-Rochereau
75014 Paris / FR
Application number, filing date15878203.713.01.2015
[2017/47]
WO2015US11148
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016114761
Date:21.07.2016
Language:EN
[2016/29]
Type: A1 Application with search report 
No.:EP3245602
Date:22.11.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 21.07.2016 takes the place of the publication of the European patent application.
[2017/47]
Search report(s)International search report - published on:US21.07.2016
(Supplementary) European search report - dispatched on:EP06.08.2018
ClassificationIPC:G06F19/00, A61K31/60, A61K31/415, A61P19/02, A61P29/00
[2018/36]
CPC:
A61K31/415 (EP,KR,US); A61K31/616 (EP,KR); A61K31/4155 (KR);
A61K31/5415 (KR); A61K31/635 (EP,KR); A61K45/06 (EP,KR);
A61K9/0053 (KR); A61P1/00 (EP); A61P11/00 (EP);
A61P11/02 (EP); A61P13/00 (EP); A61P13/12 (EP);
A61P15/00 (EP); A61P15/14 (EP); A61P17/00 (EP);
A61P19/02 (EP,KR); A61P19/08 (EP); A61P19/10 (EP);
A61P21/00 (EP); A61P25/00 (EP); A61P25/02 (EP);
A61P25/04 (EP); A61P25/06 (EP); A61P25/08 (EP);
A61P25/16 (EP); A61P25/18 (EP); A61P25/20 (EP);
A61P25/22 (EP); A61P25/28 (EP); A61P25/30 (EP);
A61P27/02 (EP); A61P27/16 (EP); A61P29/00 (EP);
A61P3/00 (EP); A61P3/06 (EP); A61P3/10 (EP);
A61P31/00 (EP); A61P35/00 (EP); A61P37/02 (EP);
A61P37/08 (EP); A61P43/00 (EP); A61P5/00 (EP);
A61P5/14 (EP); A61P7/00 (EP); A61P7/02 (EP);
A61P9/04 (EP); A61P9/06 (EP); A61P9/10 (EP);
A61P9/12 (EP); G16C20/50 (EP,KR,US); G16C99/00 (EP);
G16H20/10 (EP,US); A61K2300/00 (KR) (-)
C-Set:
A61K31/415, A61K2300/00 (EP);
A61K31/616, A61K2300/00 (EP);
A61K31/635, A61K2300/00 (EP)
Former IPC [2017/47]G06F19/00, A61K31/60, A61K31/415
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/47]
TitleGerman:VERFAHREN FÜR INDIVIDUALISIERTE KREBSTHERAPIE[2017/47]
English:METHOD FOR INDIVIDUALIZED DRUG THERAPY[2017/47]
French:MÉTHODE POUR PHARMACOTHÉRAPIE INDIVIDUALISÉE[2017/47]
Entry into regional phase14.08.2017National basic fee paid 
14.08.2017Search fee paid 
14.08.2017Designation fee(s) paid 
14.08.2017Examination fee paid 
Examination procedure04.08.2017Date on which the examining division has become responsible
14.08.2017Examination requested  [2017/47]
03.07.2019Amendment by applicant (claims and/or description)
12.02.2020Despatch of a communication from the examining division (Time limit: M04)
23.06.2020Application deemed to be withdrawn, date of legal effect  [2020/51]
11.08.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2020/51]
Request for further processing for:The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application
03.07.2019Request for further processing filed
03.07.2019Full payment received (date of receipt of payment)
Request granted
18.07.2019Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
03.07.2019Request for further processing filed
03.07.2019Full payment received (date of receipt of payment)
Request granted
18.07.2019Decision despatched
Fees paidRenewal fee
14.08.2017Renewal fee patent year 03
31.01.2018Renewal fee patent year 04
31.01.2019Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
31.01.202006   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]US2004087640  (FERRO LEONARD J [US], et al) [X] 1-11 * paragraphs [0111] , [ 112] , [ 116] , [ 145] *;
 [I]  - HAMAMA AYMAN K ET AL, "Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography", JOURNAL OF CHROMATOGRAPHIC SCIENCE, OXFORD UNIVERSITY PRESS, CARY, NC, USA, vol. 43, no. 7, doi:10.1093/CHROMSCI/43.7.351, ISSN 0021-9665, (20050731), pages 351 - 354, URL: https://epo.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV07T8MwELaABRbegvKSB1iQQp3Yjms2VCgMSCAoEkxWHCciqDRAqQT_nru4aVVggM2RzpZzZ-vu870I2WfSpoxZHfCWlIFQUgU243EgMhWrUFquGCY4P7RF91zdnIvLSZ3t7x58zZvp41v5DOqgKfiROuJVujSiBETmV_djcAWGsu9WgCEHcSxrD-ZvK0zpoEkSk89wm7IuKy3TWfrX_pbJ4siYpCde-itkJuuvkvl23cN, XP009506965 [I] 1-11 * Conclusions *

DOI:   http://dx.doi.org/10.1093/chromsci/43.7.351
International search[Y]US2006078621  (WEDINGER ROBERT S [US], et al) [Y] 1-11 * ; entire document, especially para [0001], [0004]-[0005], [0011]-[0012], [0017], [0019]-[0026], [0042], [0055]. *;
 [Y]US2007202170  (DESAI SUBHASH [US], et al) [Y] 1-11 * ; entire document, especially para [0001], [0078], [0083], [0162]-[0163], [0165], [0389]-[0390], [0412]. *;
 [Y]WO2012166795  (STRING THERAPEUTICS INC [US], et al) [Y] 3, (9-11)/(3)* ; entire document, especially pg 1, In 12-15; pg 2, In 29 to pg 3, In 3; pg 7, In 32-35; pg 8, In 9-11, 29-32; pg 12, In 14-33; pg 12, In 34 to pg 13, In 3. *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.